CALISIANT - Trademark Details
Status: 606 - Abandoned - No Statement Of Use Filed
Image for trademark with serial number 86920161
Serial Number
86920161
Word Mark
CALISIANT
Status
606 - Abandoned - No Statement Of Use Filed
Status Date
2020-06-30
Filing Date
2016-02-25
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2017-04-18
Attorney Name
Law Office Assigned Location Code
L70
Employee Name
SNYDER, NELSON B
Statements
Goods and Services
Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Translation of Words in Mark
The wording "CALISIANT" has no meaning in a foreign language.
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2016-03-01
Primary Code
005
Correspondences
Name
MATTHEW O. BRADY
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2016-02-29NEW APPLICATION ENTERED IN TRAM
2016-03-01NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2016-05-25ASSIGNED TO EXAMINER
2016-05-25NON-FINAL ACTION WRITTEN
2016-05-25NON-FINAL ACTION E-MAILED
2016-05-25NOTIFICATION OF NON-FINAL ACTION E-MAILED
2016-12-21ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
2016-12-22ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
2017-01-12TEAS PETITION TO REVIVE RECEIVED
2017-01-12PETITION TO REVIVE-GRANTED
2017-01-12TEAS RESPONSE TO OFFICE ACTION RECEIVED
2017-01-13NOTICE OF REVIVAL - E-MAILED
2017-01-14TEAS CHANGE OF CORRESPONDENCE RECEIVED
2017-02-01ASSIGNED TO LIE
2017-02-10CORRESPONDENCE RECEIVED IN LAW OFFICE
2017-02-10TEAS/EMAIL CORRESPONDENCE ENTERED
2017-02-10APPROVED FOR PUB - PRINCIPAL REGISTER
2017-03-03ASSIGNED TO LIE
2017-03-16LAW OFFICE PUBLICATION REVIEW COMPLETED
2017-03-29NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2017-04-18PUBLISHED FOR OPPOSITION
2017-04-18OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2017-06-13NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2017-11-15TEAS EXTENSION RECEIVED
2017-11-15EXTENSION 1 FILED
2017-11-15EXTENSION 1 GRANTED
2017-11-17NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2018-06-05TEAS EXTENSION RECEIVED
2018-06-05EXTENSION 2 FILED
2018-06-05EXTENSION 2 GRANTED
2018-06-07NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2018-11-01TEAS EXTENSION RECEIVED
2018-11-01EXTENSION 3 FILED
2018-11-01EXTENSION 3 GRANTED
2018-11-03NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2019-03-15TEAS EXTENSION RECEIVED
2019-03-15EXTENSION 4 FILED
2019-03-15EXTENSION 4 GRANTED
2019-03-19NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2019-12-03TEAS EXTENSION RECEIVED
2019-12-05CASE ASSIGNED TO INTENT TO USE PARALEGAL
2019-12-03EXTENSION 5 FILED
2019-12-05EXTENSION 5 GRANTED
2019-12-06NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2020-06-30ABANDONMENT - NO USE STATEMENT FILED
2020-06-30ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED